FBN1 and metabolic dysfunction-associated steatotic liver disease: To conduct an in‐depth study on the effect of asprosin on MASLD progression, mice were treated with recombinant AAV8 containing asprosin shRNA to knock down asprosin (asprosinKD) in the liver.